Skip to content
value.today

14ner Oncology, Inc.

🇺🇸 New York, New York, USAHealth CareFounded 2019
Total raised
$70 M
2 rounds on record
Latest round
$65 M
Nov 2020
First round on record
Jul 2019
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of 14ner Oncology, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2020$65 MNo. 2$50 to $250 million

14ner Oncology, Inc.: Raise no. 2, Nov 2020

Investors in this round

24 investors had bought by the notice of Nov 18, 2020: 24 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for 14ner Oncology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$65 M of $65 M offered
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Shawn Leland · Executive Officer, Director, Promoter
  • Steven Elms · Executive Officer, Director, Promoter
  • Andrew Phillips · Director
  • Colin Walsh · Director
  • Lori Hu · Director
  • Richard Gaster · Director
  • Timothy Clackson · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital, which may include normal compensation to executive officers.”

Signed by Shawn M. Leland, Ceo. Source: SEC Form D, newest notice filed Nov 18, 2020. Read the notice at the SEC.

equitySEC
Jul 2019$5 MNo. 1$2 to $10 million

14ner Oncology, Inc.: Raise no. 1, Jul 2019

Investors in this round

7 investors had bought by the notice of Jul 19, 2019: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 12 investors are named for 14ner Oncology, Inc. as a whole in other filings: see Investors below.

What the notice says

Amount sold
$5 M of $30 M offered; $25 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Shawn Leland · Executive Officer, Director
  • Steven Elms · Executive Officer, Director, Promoter
  • Lori Hu · Director
  • Michael Caldwell · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the use of proceeds: “Proceeds will be used for working capital, which may include normal compensation to executive officers.”

Signed by Steven Elms, President & CEO. Source: SEC Form D, newest notice filed Jul 19, 2019. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • 14ner Oncology, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2020).

    SEC Form D · Nov 2020

  • The industry group it chose in its notices: Other Health Care.

    SEC Form D · Nov 2020

That is all the official record says: 14ner Oncology, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

12 named in official filings. Open an investor to see everything it has backed.

Investors in 14ner Oncology, Inc.
InvestorKindAmountRoundRoleSource
Aisling Capital IV, LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Aisling Capital Partners IV LLCFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Aisling Capital Partners IV, LPFund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Asset Management, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Global Healthcare Master Fund, LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Cormorant Private Healthcare Fund III LPFund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Qiming U.S. Healthcare Fund II, L.P.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Qiming U.S. Healthcare GP II, LLCOthernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
venBio Global Strategic Fund III, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Venbio Global Strategic GP III, L.P.Fund or asset managernot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Venbio Global Strategic GP III, LTDCompanynot statednot statedHeld Series B preferred stock, 10% owner (Form 3, 2021)SEC Form 3
Vertex Global HC Fund II Pte. Ltd.Fund or asset managernot statednot statedHeld Series A and B preferred stock, 10% owner (Form 3, 2021)SEC Form 3

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 24 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by 14ner Oncology, Inc.
NameRoleNamed in
Shawn LelandExecutive officerNov 2020
Steven ElmsExecutive officerNov 2020
Andrew PhillipsDirectorNov 2020
Colin WalshDirectorNov 2020
Lori HuDirectorNov 2020
Richard GasterDirectorNov 2020
Shawn LelandDirectorNov 2020
Steven ElmsDirectorNov 2020
Timothy ClacksonDirectorNov 2020
Michael CaldwellDirectorJul 2019
Shawn LelandPromoterNov 2020
Steven ElmsPromoterNov 2020